Irinotecan (CPT-11) as first-line monotherapy in patients with advanced, metastatic colorectal cancer refractory to 5-fluorouracil adjuvant chemotherapy: A multicenter phase II study

Clinical and Translational Oncology

Volumn 4, Issue 7, 2002, Pages 385-390

  García, Matilde Navarro ^a   Gaspa, Ferrán Losa ^b   Alemany, Hermini Manzano ^c   Alfonso, Pilar García ^d   Rosales, Adolfo Murias ^e   López, Carmen Alonso ^g   Martín, Margarita García ^a   Soler, M Pérez ^f  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b Hospital Cruz Roja   (Spain)

^c HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^f Biomedical Systems SL   (Spain)

^g NONE

Author keywords

5 FU; Adjuvant; First line chemotherapy

Indexed keywords

EID: 84873476033     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993; 11:909-13.
2. Pazdur R. Irinotecan: toward clinical end points in drug development. Oncology 1998;12(Supl 6):13-21.
3. Rothenberg ML, Eckardt JR, Kuhn JG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996;14:1128-35.
4. Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretrea-ted with fluorouracil-based chemotherapy. J Clin Oncol 1997;15:251-60.
5. Pitot HC, Wender DB, O'Connell MJ, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997;15:2910-9.
6. Rothenberg ML, Cox JV, DeVore RF, et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999;85:786-95.
7. Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorec-tal cancer. J Clin Oncol 1996;14:709-15.
8. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-47.
9. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluo-rouracil for metastatic colorectal cancer. N Engl J Med 2000;343:905-14.
10. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
11. Guidelines for the reporting of adverse drugs reactions. Bethesda: Division of Cancer Treatment, National Cancer Institute; 1988.
12. Bleiberg H. Colorectal cancer. Is there an alternative to 5-FU? Eur J Cancer 1997;33:536-41.
13. Firvida JL, Irigoyen A, Vázquez-Estévez S, et al. Phase II study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma. Cancer 2001; 91:704-11.
14. Gandia D, Abigerges D, Armand JP, et al. CPT-11-indu-ced cholinergic effects in cancer patients. J Clin Oncol 1993;11:196-7.
15. Armand JP, Extra TM, Catimel G, et al. Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies. Ann Oncol 1996;7:837-42.
16. Rothenberg ML. CPT-11: an original spectrum of clinical activity. Semin Oncol 1996;23:21-6.
17. Siu LL, Rowinsky EK. A risk-benefit assessment of iri-notecan in solid tumors. Drug safety 1998;18:395-417.
18. Bleiberg H. CPT-11 in gastrointestinal cancer. Eur J Cancer 1999;35:371-9.
19. Napier M P. Ledermann JA. Novel chemotherapeutic agents in colorectal cancer. Eur J Surg Oncol 2000;26: 605-10.
20. 2 (a), or an Individual Dose Optimisation (B) or a Risk Factor Optimisation (C) in Patients (Pts) with Metastatic Colorectal Cancer (MCRC) previously Tr. Abstract, Thirty-Sixth Annual Meeting American Society of Clinical Oncology, ASCO 2000.
21. 2) as First Line Chemotherapy in Patients with Metastatic Colorectal Cancer (MCRC).